1. A PHASE 2B STUDY OF SELINEXOR IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL). (12th June 2019) Authors: Kalakonda, N.; Cavallo, F.; Follows, G.; Goy, A.; Vermaat, J.; Casasnovas, O.; Lavee, O.; Maerevoet, M.; Zijlstra, J.; Bakshi, S.; Bouabdallah, R.; Choquet, S.; Gurion, R.; Hill, B.; Jaeger, U.; Sancho, J.; Schuster, M.; Thieblemont, C.; De la Cruz, F.; Egyed, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 62 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY. (17th June 2021) Authors: Wang, M.; Rule, S.; Zinzani, P. L.; Goy, A.; Casasnovas, O.; Smith, S. D.; Damaj, G.; Doorduijn, J. K.; Lamy, T.; Morschhauser, F.; Panizo, C.; Shah, B.; Davies, A.; Eek, R.; Dupuis, J.; Jacobsen, E.; Kater, A. P.; Le Gouill, S.; Oberic, L.; Robak, T. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. BONE MARROW INVOLVEMENT, BUT NO BLOOD INVOLVEMENT, IMPAIRS SURVIVAL IN ANGIOIMMUNOBLASTIC T CELL LYMPHOMA: AN ANCILLARY STUDY OF THE REVAIL TRIAL. (12th June 2019) Authors: Lemonnier, F.; Safar, V.; Ferchiou, A.; Cottereau, A.; Bachy, E.; Cartron, G.; Moles‐Moreau, M.; Delmer, A.; Bouabdallah, R.; Voillat, L.; Parrens, M.; Casasnovas, O.; Cacheux, V.; Réguy, C.; Tilly, H.; Meignan, M.; Gaulard, P.; de Leval, L.; Delfau‐Larrue, M.; Haioun, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 278 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. CHARACTERISTICS AND OUTCOMES OF RELAPSED FOLLICULAR LYMPHOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN THE RITUXIMAB ERA. (June 2017) Authors: Sesques, P.; Golfier, C.; Boursier, J.; Bachy, E.; Traverse‐Glehen, A.; Le Gouill, S.; Casasnovas, O.; Ghesquieres, H.; Salles, G. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 220 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. EFFICACY AND SAFETY OF OBINUTUZUMAB + LENALIDOMIDE + ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL. (12th June 2019) Authors: Morschhauser, F.; Ghosh, N.; Lossos, I.; Palomba, M.L.; Mehta, A.; Casasnovas, O.; Stevens, D.; Chitra, S.; Knapp, A.; Nielsen, T.; Oestergaard, M.; Wenger, M.; Salles, G. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. EFFICACY AND SAFETY OF PROLONGED MAINTENANCE WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NHL: RESULTS OF THE PHASE III MABCUTE STUDY. (12th June 2019) Authors: Rule, S.; Barreto, W.G.; Briones, J.; Carella, A.M.; Casasnovas, O.; Pocock, C.; Wendtner, C.M.; Zaja, F.; Robson, S.; Tschopp, R.R.; Dreyling, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 229 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R‐CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY. (12th June 2019) Authors: Cottereau, A.; Vercellino, L.; Casasnovas, O.; Tilly, H.; Feugier, P.; Fruchart, C.; Roulin, L.; Oberic, L.; Pica, G.; Ribrag, V.; Abraham, J.; Simon, M.; Gonzalez, H.; Bouabdallah, R.; Fitoussi, O.; Sebban, C.; Lopez, A.; Macro, M.; Sahnes, L.; Morschhauser, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. OBINUTUZUMAB PLUS IBRUTINIB IN RELAPSE/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS: FIRST RESULTS OF THE OASIS PHASE I TRIAL. (June 2017) Authors: Le Gouill, S.; Morschhauser, F.; Bouabdallah, K.; Cartron, G.; Casasnovas, O.; Davies, A.; Chiron, D.; Rule, S. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 208 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY. (23rd June 2022) Authors: Cartron, G.; Bachy, E.; Tilly, H.; Daguindau, N.; Pica, G.-M.; Bijou, F.; Mounier, C.; Clavert, A. M.; Damaj, G. L.; Slama, B.; Casasnovas, O.; Houot, R.; Bouabdallah, K.; Sibon, D.; Fitoussi, O.; Morineau, N.; Herbaux, C.; Gastinne, T.; Fornecker, L.-M.; Haioun, C. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1023 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38). (17th June 2021) Authors: Pirosa, M. C.; Orsucci, L.; Feugier, P.; Tani, M.; Ghesquieres, Hervé; Musuraca, G.; Baldini, L.; Merli, F.; De Renzis, B.; Gyan, E.; Gini, G.; Marino, D.; Gressin, R.; Morschhauser, F.; Palombi, F.; Cavallo, F.; Conconi, A.; Le Gouill, S.; Tilly, Hervé; Zanni, M. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗